Oxidative damage from elevated production of reactive oxygen species (ROS) contributes to ischemia-reperfusion injury (IRI) in many pathologies, such as myocardial infarction, stroke, and organ transplantation. We recently determined a critical mechanism for protection from IRI by nitric oxide (NO)-dependent S-nitrosation using a mitochondria-selective S-nitrosating agent, MitoSNO. MitoSNO contains an S-nitrosating moiety derived from the NO-donor SNAP, attached to a lipophilic triphenylphosphonium cation that leads to its rapid and extensive uptake within mitochondria in vivo. Protection by MitoSNO is afforded by inhibition of complex I through selective S-nitrosation of Cys39 on the ND3 subunit, which becomes susceptible to modification only after ischaemia. The observed posttranslational alteration of complex I slows the reactivation of mitochondria during the crucial first minutes of the reperfusion of ischemic tissue, thereby decreasing ROS production, oxidative damage and tissue necrosis.
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Furthermore, we could show that the reperfusioninduced ROS production is not an unspecific event of complex I reactivation but is highly regulated by a dramatic increase in succinate during ischaemia. ROS are subsequently produced via reverse electron transport and inhibition of the succinate rise during ischaemia proved to be a further promising target to protect against IRI injury.
Taken together, reversible S-nitrosation of complex I or the prevention of ischaemic succinate accumulation results in significant protection from acute and long-term effects of IRI and provide evidence for compounds selectively targeting the mitochondria, such as MitoSNO, to be a promising therapeutic strategy for translation to use in humans. 
